This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Topical PTH (1-34)
TG Therapeutics, Inc.
Drug Names(s): Topical parathyroid hormone
Description: Topical PTH (1-34) is a parathyroid hormone-related peptide analog. It is based on a naturally occurring protein in skin and hair follicles that serves to regulate the growth of skin cells. Topical PTH (1-34) uses IGI's Novasome nano-vesicular topical delivery technology.
Deal Structure: In May 2004, IGI reported that it signed a sublicense agreement with Tarpan Therapeutics for the clinical uses of PTH 1-34 relating the regulation of cell differentiation and proliferation for treatment of skin disorders using IGI's Novasome Delivery Technology. Under the terms of the agreement, Tarpan will assume all costs for clinical trials and pay IGI an upfront payment, milestone and royalty payments.
In April 2005, Manhattan Pharmaceuticals acquired Tarpan Therapeutics in an all stock transaction that resulted in Tarpan shareholders owning approximately 20% of the shares of Manhattan on a fully-diluted basis.
In May 2009, Manhattan Pharmaceuticals terminated the agreement with IGI for Topical PTH (1-34) and has no further financial liability or commitment to IGI under the license agreement.
In April 2012, Manhattan Pharmaceuticals filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals to TG Therapeutics.
Topical PTH (1-34) News
Additional information available to subscribers only: